CTOs on the Move


 
Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Shasqi raised $10M on 10/31/2019

Similar Companies

Arixa Pharmaceuticals

Arixa Pharmaceuticals™ is developing oral antibiotics for resistant Gram-negative infections, an urgent need. Our lead program is an oral prodrug of Avibactam®, a broad spectrum beta-lactamase inhibitor recently approved by FDA. We have addressed and solved the medicinal chemistry issues which complicate the prodrugging of this class of compounds, and expect to receive broad composition of matter patent protection.

Tidal Vision

Chitosan manufacturer and supplier of ready-to-use chitosan flocculants, textile treatments, and agricultural elicitor applications.

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

AAI Pharmaceutical

AAI Pharmaceutical is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marengo Therapeutics

Marengo Therapeutics is pioneering an entirely new way to activate the body`s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.